🚀Upper GI oral abstracts #ESMO26 Day 1 summary results

1) Arcotatug tavatecan improved PFS in CLDN18.2+ G/GEJA in the 3L+ setting

2) SANO trial, OS at 5 years similar between active surveillance and surgery in patients with oesophageal cancer and a complete clinical response after nCR, despite more distant metastasis

3) Adding pembrolizumab to dCRT did not improve EFS in untreated unresectable esophageal or GEJ cancer with PD-L1 CPS ≥10

4) Daraxonrasib demonstrated consistent OS benefit in different RAS mutatin subgroups in RASolute-302

5) mKRAS-specific lymph node targeted amphiphile immunotherapy in PDAC did not met primary DFS endpoint.

6) Zani + CT +/- tisle keep OS benefit in at IA2 of HERIZON-GEA-01

7) Anbenitamab plus ChT improved OS in patients with HER2-positive GC/GEJC adenoca after previous trastuzumab

8) TQB2102 (HER2 bispecific antibody-drug conjugate) plus bemotrizumab and capecitabine demonstrates promising antitumor activity in 1L of advanced GC/GEJC

9) Dostarlimab in Pts with localized dMMR/MSI-H GEA led to a 62.5% 1y-cCR at the first interim analysis, enabling organ preservation.

10) FOLFIRI and Ram vs paclitaxel in taxan-pretreated GEA imporved PFS but no OS

11) Stage II–IIIB gastric cancer after D2 resection, four months of adjuvant XELOX was noninferior to six months for 3-year DFS

12) Adding durvalumab to dCRT in locally advanced esophagus carcinoma did not improve PFS

13) Adding SBRT to MFOLFIRINOX in high risk, borderline resectable or locally advanced pancreatic cancer mproved LRR and PFS

14) FGFR2b expressing GC/GEJ with co-existing FGFR2 amp may define a biologically distinct subset with potential sensitivity to bemarituzumab

#cancer #oncology #MedX #GI #gastrointestinal @OncoAlert